Georgian medical news · 2024
EFFECTIVENESS AND TOLERABILITY OF APREMILAST IN TREATMENT OF A SAMPLE OF PATIENTS WITH PSORIASIS.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdul-Reda F, Al-Zobaidy M
Аннотация
AIM: Current study was aimed to appraise the effectiveness and tolerability of apremilast in psoriasis patients at AL-Diwaniyah province, Iraq.
MATERIALS AND METHODS: This prospective cross-sectional study conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq, during the period from January to October 2023. A total of 125 patients, 90 males and 35 females, were enrolled in this study. Patients who were eligible were treated for 6 months using apremilast at a dose of 30 mg/day. Psoriasis Area and Severity Index scoring system was used for assessment of patients' response to treatment. Data were analyzed using the Statistical Package for Social Sciences (version 26).
RESULTS: Data from current study revealed that there was a significant reduction of mean PASI score from 20.37±6.25 at baseline to 3.72±2.09 after 6 months of treatment (p<0.001).
CONCLUSION: Apremilast is effective in reducing PASI mean score with negligible adverse effects. However, multi-center studies are needed to establish its efficacy and safety in Iraqi patients with psoriasis.
MATERIALS AND METHODS: This prospective cross-sectional study conducted at Dermatology Unit/ AL-Diwaniyah Teaching Hospital/ Iraq, during the period from January to October 2023. A total of 125 patients, 90 males and 35 females, were enrolled in this study. Patients who were eligible were treated for 6 months using apremilast at a dose of 30 mg/day. Psoriasis Area and Severity Index scoring system was used for assessment of patients' response to treatment. Data were analyzed using the Statistical Package for Social Sciences (version 26).
RESULTS: Data from current study revealed that there was a significant reduction of mean PASI score from 20.37±6.25 at baseline to 3.72±2.09 after 6 months of treatment (p<0.001).
CONCLUSION: Apremilast is effective in reducing PASI mean score with negligible adverse effects. However, multi-center studies are needed to establish its efficacy and safety in Iraqi patients with psoriasis.